Trial Profile

Phase 1b & 2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (VIRO-15)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 31 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olvimulogene nanivacirepvec (Primary) ; Antineoplastics; Bevacizumab; Carboplatin
Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions; Biomarker; Therapeutic Use
Acronyms VIRO-15
Sponsors Genelux Corporation

Most Recent Events

25 May 2023 Primary endpoint (Overall Response Rate (ORR) by RECIST 1.1 (Phase 2)) has been met, according to a Genelux Corporation media release.
25 May 2023 According to a Genelux Corporation media release, topline results of this study published in JAMA Oncology.
25 May 2023 Results presented in a Genelux Corporation Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com